CRISPR Therapeutics PE ratio CRSP

Share price divided by earnings per share over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 22.5×; Aug 2022
7-year median: 22.9×
7-year range: 10.9× to 239×
Peer median: 29.3×

CRISPR Therapeutics has no meaningful PE ratio today: it lost $4.76 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Aug 2022, at 22.5×.

On the days it had one over the last 7 years, its median was 22.9×, from 10.9× in May 2022 to 239× in Oct 2020.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	22.5×	10.9×	23.1×
2021	15.9×	14.7×	26.8×
2020	201×	38.8×	239×

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

Company	PE ratio
CRSPCRISPR Therapeutics	n/m
KRYSKrystal Biotech	39.0×
ADMAAdma Biologics	15.3×
RGENRepligen	242×
VCELVericel	92.5×
TECHBIO-TECHNE	63.1×
HALOHalozyme Therapeutics	37.5×
NBIXNeurocrine Biosciences	20.9×
EXELExelixis	20.3×
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
Peer median	29.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.